Shanghai Medicilon Inc.’s Net Profit Rose 2.2% in First Half of 2023

Shanghai Medicilon Inc. (上海美迪西生物医药股份有限公司) (688202.SH) reported a net profit of 166.1 million yuan in the first half of 2023, up 2.2% year-on-year.

Meanwhile, the company posted 872.3 million yuan in revenue, up 17.4% year-on-year.

At the end of the reporting period, it had 2.6 billion yuan in total assets and 861 million yuan in total liabilities, with a liability-to-asset ratio of 33.2%.